Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6492
    -0.0008 (-0.12%)
     

  • OIL

    83.04
    +0.23 (+0.28%)
     

  • GOLD

    2,330.10
    -8.30 (-0.35%)
     

  • Bitcoin AUD

    97,510.76
    -4,423.38 (-4.34%)
     

  • CMC Crypto 200

    1,346.04
    -36.53 (-2.64%)
     

  • AUD/EUR

    0.6070
    -0.0000 (-0.00%)
     

  • AUD/NZD

    1.0955
    +0.0013 (+0.12%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,220.83
    -305.97 (-1.75%)
     

  • FTSE

    8,051.31
    +10.93 (+0.14%)
     

  • Dow Jones

    37,926.09
    -534.83 (-1.39%)
     

  • DAX

    17,862.65
    -226.05 (-1.25%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Liquidia Technologies, Inc.
·1-min read

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:20am Eastern time.

A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the Company’s corporate website, and will be archived for a minimum of 90 days.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information

Investor Relations:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com